The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030 <Roots Analysis>

Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.”

 

The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. It features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

• A detailed review of the current landscape of companies offering contract manufacturing services.
• Elaborate profiles of key players that specialize in offering services for contract biomanufacturing.
• A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
• An analysis of the partnerships and expansions that have been established in this domain, in the recent past.
• A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.
• A detailed proprietary 2×2 representation to assess the current market scenario
• An analysis of the initiatives of big biopharma players engaged in this domain.
• Majority of the players have the necessary infrastructure / capability to produce different biologics, primarily proteins, at all scales using bacterial / yeast expression vectors
• The market features the presence of several well-established players across the globe; the US, the UK and Germany emerged as current hubs for production of biologics using microbial strains
• Several service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective service portfolio and maintain a competitive edge in the industry
• The growth trend of outsourcing microbial manufacturing operations is evident from the rise in recent partnership activity, as well as expansion initiatives undertaken by CMOs to meet the growing demand for novel biologics
• Big pharma players have also made significant investments in this domain through establishment of new facilities, entering into strategic collaborations and undertaking financial investments
• Future growth of the market is likely to be driven by increased adoption of novel biologics that are produced via microbial systems; we expect the service-based revenues to grow at a CAGR of over 8%
• In the long term, the projected opportunity for contract biomanufacturing is anticipated to be distributed across contract service providers of different sizes, scales of manufacturing and key geographical regions
• A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
• Type of Product
• API
• FDF

 

• Type of Biologic

• Proteins
• Enzymes
• Growth Hormones
• Antibody based Drugs
• Others (plasmid DNA, probiotics, microbiome-based biologics)

 

• Type of Microbial Expression System

• Bacteria
• Yeast
• Others (Algae and fungi)

 

• Scale of Operation
• Commercial
• Preclinical / Clinical

 

• Type of End User
• Small Companies
• Mid-sized Companies
• Large / Very Large Companies

 

• Key Geographical Regions
• North America
• Europe
• Asia Pacific
• Middle East and North Africa
• Latin America

 

 

Key companies covered in the report

• AGC Biologics
• Aldevron
• BioVectra
• EirGenix
• Etinpro
• Eurogentec
• Northway Biotechpharma
• Ology Bioservices
• Porton Biopharma
• Stelis Biopharma

 

For additional details, please visit

https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email [email protected]

 

You may also be interested in the following titles:

1. Drug Repurposing Service Providers Market, 2020 – 2030
2. Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030
3. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030

 

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

[email protected]